Promising Pipeline and Clinical Progress Drive Buy Rating for Artelo Biosciences

Analyst Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Artelo Biosciences (ARTL – Research Report) and keeping the price target at $5.00.

Vernon Bernardino’s rating is based on the promising clinical developments within Artelo Biosciences’ pipeline, particularly the progress of their investigational drug ART27.13. This drug is in Phase 2 of clinical development and is anticipated to reach significant milestones by 2025. ART27.13 has shown encouraging preliminary results in treating cancer-related cachexia, a condition for which there are currently no approved therapies, making it a potentially high-value asset.
Additionally, Artelo’s other pipeline candidates, such as ART26.12 and ART12.11, are also progressing well. ART26.12 is being evaluated for neuropathic pain and has demonstrated positive preclinical results, while ART12.11 is showing promise as an alternative formulation of CBD with improved bioavailability. These developments suggest that Artelo Biosciences has a robust pipeline with multiple potential catalysts for growth, supporting Bernardino’s Buy rating.